SBTi Registry
Explore 1 matching companies with public, verified Science Based Targets commitments.
Data sourced from the Science Based Targets initiative (SBTi).
| Sector | Region | Near-Term Status | Size | ||||
|---|---|---|---|---|---|---|---|
| Santen Pharmaceutical Co., Ltd | Pharmaceuticals, Biotechnology and Life Sciences | Asia | Targets set | Medium | 4 | Jul 21, 2021 | |
Near-Term Status Targets set Near-Term Classification 1.5°C Near-Term Target Year - Long-Term Status - Net-Zero Status - Net-Zero Year - Sector Pharmaceuticals, Biotechnology and Life Sciences Region Asia Organization Type Corporate Location Japan Company Size Medium Target Statement Santen Pharmaceutical Co. , Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 50% by FY 2030 from a FY 2019 base year. Santen Pharmaceutical Co. , Ltd. also commits to reduce absolute scope 3 GHG emissions from purchased goods and services 15% within the same timeframe. Stakeholders Takahiro Morita Global Head of Core Principle & Sustainability Director, Head of Procurement Head of Procurement (Asia) Senior Director, Global External Manufacturing and Sourcing | |||||||
Turn Commitments Into Impact
Thousands of companies have set public Scope 3 emissions-reduction targetsthrough SBTi, but few have the tools to deliver on them. Carbon3 gives you the infrastructure to plan, track, and execute the supply-chain decarbonization work behind your commitment, turning a public pledge into measurable progress. See how it works.